| Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre |
ACTRN12612000473864: A randomised phase 2 study of carboplatin with oral vinorelbine followed by maintenance therapy with oral vinorelbine or erlotinib in elderly patients with metastatic non-small cell lung cancer. |
|
|
| Not yet recruiting | 2 | 100 | | | Southern Health, Pierre Fabre | Non Small Cell Lung Cancer | | | | |
ACTRN12609000003279: Cisplatin and oral vinorelbine chemotherapy along with radiation for treatment of locally advanced lung cancer |
|
|
| Recruiting | 2 | 50 | | | Royal Adelaide Hospital, Pierre Fabre Medicament Pvt Ltd | Stage III Non Small Cell Lung Cancer | | | | |
| Recruiting | 2 | 20 | | | North Shore Hospital , Prathima Chowdary | ECTOPIC PREGNANCY | | | | |
| Ongoing | 2 | 200 | Europe | Navelbine, Capsule, Navelbine | University of Leicester, Pierre Fabre Ltd | Histologically confirmed malignant pleural mesothelioma, Mesothelioma, Diseases [C] - Cancer [C04] | | | | |
2014-003860-19: Study comparing oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer. |
|
|
| Ongoing | 2 | 160 | Europe | Capsule, soft, Navelbine 20mg soft capsules, Navelbine 30mg soft capsules | PIERRE FABRE MEDICAMENT, Pierre Fabre Medicament | Advanced Breast Cancer, Breast Cancer, Diseases [C] - Cancer [C04] | | | | |
2006-003752-38: A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer |
|
|
| Ongoing | 2 | 43 | Europe | XELODA*120CPR RIV 500MG, NAVELBINE*1CPS 30MG, XELODA*60CPR RIV 150MG, XELODA*120CPR RIV 500MG, NAVELBINE*1CPS 30MG, XELODA*60CPR RIV 150MG | OSPEDALE ONCOLOGICO DI BARI | advancer breast carcinoma | | | | |
2004-000665-35: Study to assess the efficacy and safety of oral vinorelbine in combination with capecitabine in patients suffering from breast cancer previously treated with other chemotherapies (anthracyclines, and taxanes) Estudio para evaluar la eficacia y seguridad de vinorelbina oral en combinación con capecitabina en pacientes con cáncer de mama previamente tratadas on otras quimioterapias (antraciclinas y taxanos) |
|
|
| Ongoing | 2 | 15 | Europe | Navelbine Cápsulas Blandas, Xeloda, Not applicable, Navelbine Capsulas blandas, Xeloda, Navelbine Capsulas blandas, Xeloda | Pierre Fabre Medicament, Pierre Fabre Medicament | Treatment in metastatic breast cancer women previously treated with anthracyclines and taxanes | | | | |
2004-000748-26: Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer. |
|
|
| Ongoing | 2 | 12 | Europe | Navelbine Cápsulas Blandas, Xeloda, Herceptin 150 mg, Not applicable, Navelbine Cápsulas Blandas, Xeloda 500 mg 120 commprimidos cubierta pelicular, Herceptin 150 mg, Navelbine Cápsulas Blandas, Xeloda 500 mg 120 commprimidos cubierta pelicular, Herceptin 150 mg | Pierre Fabre Ibérica, S.A. en representación de Pierre Fabre Mèdicament | Treatment in women with previously untreated HER2 positive metastatic breast cancer. | | | | |
2004-000753-30: Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer. |
|
|
| Ongoing | 2 | 15 | Europe | Navelbine Soft Capsules, Xeloda, Not applicable, NA, Navelbine Cápsulas Blandas, Xeloda 500 mg 120 comprimidos cubierta pelicular, Navelbine Cápsulas Blandas, Xeloda 500 mg 120 comprimidos cubierta pelicular | Pierre Fabre Ibérica S.A. as legal representative of Pierr Fabre Mèdicament | Treatment in women with previously untreated HER2 negative metastatic breast cancer. | | | | |
2009-015658-39: A PILOT STUDY TESTING THE FEASIBILITY OF TWO DIFFERENTS REGIMENS INCORPORATING DOSE-DENSE DOCETAXEL AND CAPECITABINE-ORAL VINORELBINE IN THE ADJUVANT TREATMENT OF EARLY BREAST CANCER PATIENTS |
|
|
| Ongoing | 2 | 30 | Europe | Concentrate for solution for infusion, Concentrate for solution for injection, Powder and solvent for solution for infusion, Film-coated tablet, Capsule, soft | AZIENDA USL 4 PRATO | BREAST CANCER | | | | |
2007-000439-24: NORA TRIAL (oral Navelbine in adjuvabt):multicenter,prospective,phase II, randomized clinical trial concerning about adjuvant chemioterapy with cisplatino and vinorelbine according to an advanced schedule in the lung cancer with small cells. |
|
|
| Ongoing | 2 | 122 | Europe | NAVELBINE, CISPLATINO TEVA, NAVELBINE, CISPLATINO TEVA | OSPEDALE S. RAFFAELE | patients underwent complete surgery for non small cel lung cancer | | | | |
2006-002152-16: Phase II randomized study of intravenous bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine in patients with locally advanced or recurrent breast cancer with lymphangitic spread to the chest wall. |
|
|
| Ongoing | 2 | 46 | Europe | AVASTIN*INFUS 1FL 400MG, NAVELBINE*1CPS 30MG, XELODA*120CPR RIV 500MG, NAVELBINE*1CPS 20MG, AVASTIN*INFUS 1FL 100MG, XELODA*60CPR RIV 150MG, AVASTIN*INFUS 1FL 400MG, NAVELBINE*1CPS 30MG, XELODA*120CPR RIV 500MG, NAVELBINE*1CPS 20MG, AVASTIN*INFUS 1FL 100MG, XELODA*60CPR RIV 150MG | ISTITUTO EUROPEO DI ONCOLOGIA | locally advanced or recurrent breast cancer with lymphangitic spread to the chest wall. | | | | |
2010-018762-23: METRONOMIC ORAL VINORELBINE IN ADVANCED (STAGE IIIB-IV) NON-SMALL CELL LUNG CANCER PATIENTS: A PHASE II TRIAL (MOVE Trial � ASL1209/001) |
|
|
| Ongoing | 2 | 48 | Europe | NAVELBINE*1CPS 20MG, NAVELBINE*1CPS 30MG, NAVELBINE*1CPS 20MG, NAVELBINE*1CPS 30MG | AZIENDA UNITA, SANITARIA LOCALE N 12 DI VIAREGGIO | ADVANCED (STAGE IIIB-IV) NON-SMALL CELL LUNG CANCER | | | | |
2010-022183-12: Phase II study of metronomic oral Vinorelbine plus Bevacizumab as first line treatment for metastatic breast cancer patients |
|
|
| Ongoing | 2 | 46 | Europe | NAVELBINE*1CPS 20MG, NAVELBINE*1CPS 30MG, AVASTIN*INFUS 1FL 100MG 4ML, AVASTIN*INFUS 1FL 400MG 16ML, NAVELBINE*1CPS 20MG, NAVELBINE*1CPS 30MG, AVASTIN*INFUS 1FL 100MG 4ML, AVASTIN*INFUS 1FL 400MG 16ML | ISTITUTO EUROPEO DI ONCOLOGIA | Metastatic breast cancer | | | | |
2016-002674-12: A study to evaluate the effectof oral Vinorelbine vs the best treatmentof support as maintenance therapy after chemotherapy with taxanes in patients with breast cancer Estudio para evaluar el efecto de Vinorelbina oral frente al mejor tratamiento de soporte como mantenimiento después de quimioterapia con taxanos en pacientes con cáncer de mama. |
|
|
| Ongoing | 2 | 125 | Europe | Nabelvine, SUB00069MIG, Capsule, soft, Navelbine 30mg, Navelbine 20mg | Asociación Terapéutica Investigación Oncológica (ATRIO), Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Pierre Fabre Iberica S.A. | Metastatic breast cancer Cáncer de mama metastásico, Breast cancer Cáncer de mama, Diseases [C] - Cancer [C04] | | | | |
2016-002165-63: A direct comparison of Oral Navelbine given either classic or metronomic in metastatic breast cancer En direkte sammenligning af Navelbine Oral (Vinorelbine) kemoterapi givet enten klassisk eller metronomisk til behandling af patienter med metastaserende brystkræft. |
|
|
| Ongoing | 2 | 200 | Europe | Navelbine, L01CA, Capsule, soft, Navelbine | Aarhus University Hospital, Kræftafdelingen, Aarhus university Hospital | Breastcancer, breastcancer, Diseases [C] - Cancer [C04] | | | | |
Spring-Lung 6, ChiCTR-IIR-17012197: A phase II, open-label, randomised controlled trial of icotinib with and without metronomic oral vinorelbine as first-line therapy in patients with EGFR mutation-positive advanced nonsquamous non–small-cell lung cancer. |
|
|
| Not yet recruiting | 2 | 120 | | Icotinib 125mg orally(PO) tid + vinorelbine 40mg po three times weekly (Monday-Wednesday-Friday) continuously until disease progression, unacceptable toxicity or patient refusal. ;Icotinib 125mg orally(PO) tid continuously until disease progression, unacceptable toxicity or patient refusal. | Shandong Cancer Hospital and Institute; Shandong Cancer Hospital and Institute, The 13th five-year major new-drug-initiative project | non-small cell lung cancer | | | | |
NCT03854617: A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer |
|
|
| Not yet recruiting | 2 | 172 | NA | Oral NVB Metronomic, Oral Navelbine Metronomic, Oral NVB Weekly, Oral Navelbine Weekly | Chinese Academy of Medical Sciences | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | 12/21 | 12/25 | | |
| Completed | 2 | 140 | Europe | Paclitaxel, Paclitaxel Sandoz, Cyclophosphamide, Endoxan Baxter, Capecitabine, Xeloda, Vinorelbine, Navelbine | ETOP IBCSG Partners Foundation | Breast Cancer | 11/21 | 11/22 | | |
NCT03932526: Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 184 | NA | Vinorelbine + placebo, AiTan+ placebo, Vinorelbine + Apatinib, Navelbine+AiTan | Liaoning Tumor Hospital & Institute | Triple-negative Breast Cancer | 12/22 | 06/23 | | |
NCT05747326: Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer |
|
|
| Recruiting | 2 | 30 | RoW | oral vinorelbine and capecitabine, metronomic agents (vinorelbine and capecitabine ) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer | 06/23 | 06/23 | | |
NCT04021992: GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL |
|
|
| Recruiting | 2 | 48 | RoW | gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab | Sun Yat-sen University | Lymphoma, Large B-Cell, Diffuse | 07/23 | 12/23 | | |
NCT03703427: Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy |
|
|
| Not yet recruiting | 2 | 200 | RoW | Capecitabine, Oral, 500 Mg, Vinorelbine Tartrate Oral | Zhiyong Yu | Pathologic Residual Cancer Cells | 11/23 | 11/25 | | |
NCT05823623: Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate | The First Affiliated Hospital with Nanjing Medical University | Breast Cancer | 12/23 | 12/25 | | |
VEX, NCT04304352: Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients |
|
|
| Recruiting | 2 | 162 | Europe | Vinorelbine, Metronomic Vinorelbine, Capecitabine, Metronomic Capecitabine, Cyclophosphamide, Metronomic Cyclophosphamide | European Institute of Oncology | Advanced Breast Cancer | 12/23 | 12/23 | | |
NCT06229067: Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 182 | NA | Adebrelimab, Vinorelbine, Cyclophosphamide (tablet), Capecitabine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer, Triple Negative Breast Cancer | 01/25 | 01/27 | | |
NCT06260553: Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC |
|
|
| Enrolling by invitation | 2 | 40 | RoW | tislelizumab and metronomic oral vinorelbine | Fujian Cancer Hospital | EGFR/ ALK-negative Advanced NSCLC | 02/25 | 08/25 | | |
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer |
|
|
| Recruiting | 2 | 105 | Europe, Japan, US, RoW | Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide | Eli Lilly and Company | Neoplasms, Child, Adolescent | 05/26 | 05/26 | | |
NCT05826964: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer |
|
|
| Recruiting | 2 | 500 | US | AI+CDK4/6i, Aromatase Inhibitor (AI) + Cyclin dependent kinase 4 and 6 inhibitor (CDK4/6i), Anastrozole, Letrozole, Exemestane, Palbociclib, Ribociclib, Abemaciclib, SERD+CDK4/6i, Selective Estrogen Receptor Degrader (SERD) + CDK4/6i, Fulvestrant, mTOR inhibitor + AI, Mammalian target of rapamycin (mTOR) inhibitor + Aromatase Inhibitor (AI), Everolimus, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, Tamoxifen, PI3K inhibitor + SERD, Phosphoinositide 3-kinase (PI3K) inhibitor + SERD, Alpelisib, PI3K inhibitor + AI, Chemotherapy, Taxane, Eribulin, Capecitabine, Vinorelbine, Oral SERD, Elacestrant | University of Miami | Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer | 07/26 | 07/29 | | |
| Recruiting | 2 | 28 | US | Vincristine, Cyclophosphamide, Vinorelbine, Navelbine, Actinomycin D, Cosmegen, Cyclophosphamide Pill | H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation | Rhabdomyosarcoma | 12/26 | 12/27 | | |
2004-000602-44: Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado |
|
|
| Ongoing | 1/2 | 63 | Europe | Navelbine cápsulas blandas, Xeloda, NA, Navebine Cápsulas Blandas, Xeloda 500, 100 mg, Navebine Cápsulas Blandas, Xeloda 500, 100 mg | Pierre Fabre Ibérica, S.A. | Advanced breast cancer (metastatic) | | | | |
2017-001857-14: A phase I/II basket trial evaluating a combination of Metronomic Oral Vinorelbine plus anti-PD-L1/anti-CTLA4 ImmunothErapy in patients with advanced solid tumours. |
|
|
| Not yet recruiting | 1/2 | 159 | Europe | Durvalumab, Tremelimumab, MEDI4736, Capsule, soft, Solution for injection, NAVELBINE | UNICANCER, Astra Zeneca, Pierre Fabre, Programme Hospitalier de Recherche Clinique | Patients with Histologically confirmed locally advanced or metastatic solid tumours, resistant to conventional therapies, and candidate to experimental therapy by local clinical board, from the following primary tumours: head and neck, prostate, cervix, and breast cancers, as well as miscellaneous malignancies with high mutational load., Patients with locally advanced or metastatic solid tumours, Diseases [C] - Cancer [C04] | | | | |
MOVIE, NCT03518606: Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours |
|
|
| Active, not recruiting | 1/2 | 126 | Europe | Durvalumab + Tremelimumab + metronomic Vinorelbine | UNICANCER, National Cancer Institute, France, AstraZeneca, Pierre Fabre Laboratories | Advanced Solid Tumours, Breast Cancer, Head and Neck Cancer, Cervix Cancer, Prostate Cancer | 04/22 | 12/24 | | |
| Active, not recruiting | 1/2 | 34 | Europe, Japan, US, RoW | Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine | Eli Lilly and Company | Desmoplastic Small Round Cell Tumor | 06/24 | 10/24 | | |
NCT06023641: Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease |
|
|
| Recruiting | 1/2 | 100 | US | Vincristine, Oncovin, Dactinomycin, (actinomycin-D), Cyclophosphamide, Cytoxan®., Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, (Onivyde®), Vinorelbine, Navelbine, Temozolomide, Temodar, Filgrastim, peg-filgrastim, Neupogen | St. Jude Children's Research Hospital | Rhabdomyosarcoma | 10/34 | 10/37 | | |
